Abstract

 CADTH recommends that Palynziq should be reimbursed by public drug plans for the treatment of patients with phenylketonuria (PKU) aged 16 years and older who have inadequate blood phenylalanine control (blood phenylalanine levels greater than 600 µmol/L) on existing management if certain conditions are met.
 Palynziq should only be covered to treat patients with PKU aged 16 years and older.
 Palynziq should only be reimbursed for patients who demonstrate and maintain a response to treatment (blood phenylalanine levels less than 600 µmol/L), if the drug is prescribed by a clinician with expertise in treating genetic and metabolic disorders, and if the cost of Palynziq is reduced.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
